The Merck Manuals is proud to be an independent (non-government) medical information resource integrated into this platform. This collaboration exemplifies a commitment to enhancing clinical workflows ...

In a new editorial from MerckManuals.com, Ashley B. Grossman, MD, University of Oxford; Fellow, Green-Templeton College, addresses common patient questions around Cushing syndrome. 1. What causes ...

Merck MRK announced that the FDA has accepted its regulatory filing seeking approval for the subcutaneous (under the skin or SC) formulation of the blockbuster drug Keytruda (pembrolizumab). This ...

NEW YORK, March 27 (Reuters) - Merck & Co (MRK.N) said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the U.S. on October ...

NEW YORK (Reuters) – Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the U.S. on October 1, and expects to hit ...

New Version of Merck’s Blockbuster Cancer Drug Threatened by Patent Battle The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda ...

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech Halozyme Therapeutics , the Wall Street Journal reported on Wednesday, citing ...

Conversational artificial intelligence platform Perplexity plans to roll out a pro version of its AI platform for students in India free of charge. During an online session with Paytm founder and CEO ...

Translation of: The Merck Manual of medical information - Home edition Includes index Fundamentos -- Fármacos -- Enfermedades cardiovasculares -- Trastornos del aparato respiratorio -- Trastornos de ...

The latest version of Keytruda could eventually capture between 30% and 40% of the market for the original, Merck CEO Rob Davis said at the JPMorgan Healthcare Conference in San Francisco on Monday.

Merck & Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end of the year, accelerating the company’s efforts to protect its top ...